Biotech IPOs continue attracting cash 

A trio of IPOs on Friday continued the trend of strong debuts by biotech companies on NASDAQ. The offerings from Recursion, Biomea and Akoya all priced at the top of their range and traded up in the aftermarket. 

Investors will be tracking how well the stocks perform in the near term as IPO performance is one of the key metrics investors are tracking this quarter to gauge whether 1Q21’s record financing activity is going to start to slow...